Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - esomeprazole, quantity: 20 mg - capsule, enteric - excipient ingredients: glyceryl monostearate; mannitol; methacrylic acid - ethyl acrylate copolymer (1:1); polysorbate 80; hyprolose; crospovidone; triethyl citrate; purified talc; sodium hydroxide; sucrose; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; iron oxide red; gelatin; sodium lauryl sulfate; maize starch - noxicid is indicated for: 1. gastro-oesophageal reflux disease (gord) - treatment of erosive reflux oesophagitis - long-term management of patients with healed oesophagitis to prevent relapse - symptomatic treatment of gastro-oesophageal reflux disease (gord) 2. patients requiring nsaid therapy - short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy. - healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy - prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk. 3. pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion 4. in combination with appropriate antibiotics for: - healing of duodenal ulcer associated with helicobacter pylori - eradication of helicobacter pylori in patients with active or healed peptic ulcer.

Israel - English - Ministry of Health

bristol, myers squibb (israel) limited, israel - elotuzumab - powder for concentrate for solution for infusion - elotuzumab 300 mg/vial - elotuzumab - empliciti is indicated in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.empliciti is indicated in combination with pomalidomide and dexamethasone for the treatment ofadult patients with relapsed and refractory multiple myeloma who have received at least two priortherapies, including lenalidomide and a proteasome inhibitor, and have demonstrated diseaseprogression on the last therapy.

Israel - English - Ministry of Health

bristol, myers squibb (israel) limited, israel - elotuzumab - powder for concentrate for solution for infusion - elotuzumab 400 mg/vial - elotuzumab - empliciti is indicated in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.empliciti is indicated in combination with pomalidomide and dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor, and have demonstrated disease progression on the last therapy.

Ireland - English - HPRA (Health Products Regulatory Authority)

sol s.p.a. - oxygen - medicinal gas, compressed - 21.75 percent volume/volume - medical gases; oxygen

Australia - English - Department of Health (Therapeutic Goods Administration)

air liquide healthcare pty ltd - oxygen, quantity: 1 l/l - gas, medicinal - excipient ingredients: - for respiratory delivery where there is a requirement for medicinal oxygen to treat or prevent hypoxemia.

Singapore - English - HSA (Health Sciences Authority)

goldplus universal pte ltd - rifampicin - capsule - rifampicin 150mg

Singapore - English - HSA (Health Sciences Authority)

goldplus universal pte ltd - rifampicin - capsule - rifampicin 300mg

European Union - English - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - elotuzumab - multiple myeloma - antineoplastic agents - empliciti is indicated in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in adult patients who have received at least one prior therapy (see sections 4.2 and 5.1).

United States - English - NLM (National Library of Medicine)

bayer healthcare pharmaceuticals inc. - praziquantel (unii: 6490c9u457) (praziquantel - unii:6490c9u457) - praziquantel 600 mg - biltricide is indicated in patients aged 1 year and older for the treatment of the following infections: biltricide is contraindicated in:

United States - English - NLM (National Library of Medicine)

central texas community health centers - praziquantel (unii: 6490c9u457) (praziquantel - unii:6490c9u457) - praziquantel 600 mg - biltricide is indicated for the treatment of infections due to: all species of schistosoma (for example, schistosoma mekongi, schistosoma japonicum, schistosoma mansoni and schistosoma hematobium ), and infections due to the liver flukes, clonorchis sinensis/opisthorchis viverrini (approval of this indication was based on studies in which the two species were not differentiated). biltricide is contraindicated in patients who previously have shown hypersensitivity to the drug or any of the excipients. since parasite destruction within the eye may cause irreversible lesions, ocular cysticercosis must not be treated with this compound. concomitant administration with strong cytochrome p450 (p450) inducers, such as rifampin, is contraindicated since therapeutically effective blood levels of praziquantel may not be achieved (see precautions/drug interactions). in patients receiving rifampin who need immediate treatment for schistosomiasis, alternative agents for schistosomiasis should be considered. however, if